Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.

Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.

UNLABELLED: Multidrug resistance (MDR) is a major challenge to the successful treatment of acute myeloid leukemia (AML). Our purpose was to determine whether (111)In-HuM195 anti-CD33 antibodies modified with peptides harboring nuclear localizing sequences (NLS) could kill drug-resistant AML cell li...

Full description

Bibliographic Details
Main Authors:	Kersemans, V, Cornelissen, B, Minden, MD, Brandwein, J, Reilly, R
Format:	Journal article
Language:	English
Published:	2008

Similar Items

Indium-111 labeled anti-CD33 monoclonal antibodies (mAbs) modified with nuclear-localizing sequences (NLS) kill mitoxantrone-resistant HL-60 acute myelogenous leukemia (AML) cells
by: Kersemans, V, et al.
Published: (2006)

Monoclonal antibodies differentiating between monocytic and nonmonocytic variants of AML.
by: Linch, D, et al.
Published: (1984)

CYTOLOGICAL FEATURES WITH PROGNOSTIC-SIGNIFICANCE IN AML
by: Swirsky, D, et al.
Published: (1983)

Mechanisms of response and resistance to AML therapies
by: Stoilova, B, et al.
Published: (2020)

The graft-versus-leukemia effect in AML
by: Sweeney, C, et al.
Published: (2019)

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials
by: Gale, R, et al.
Published: (2018)

The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial.
by: Grimwade, D, et al.
Published: (1999)

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
by: Hoyle, C, et al.
Published: (1989)

Impact of diagnostic cytogenetics on outcome in AML: Analysis of 1,613 patients entered into the UK MRC AML 10 trial.
by: Grimwade, D, et al.
Published: (1996)

Del(9q) AML: Clinical, cytological and cytogenetic characteristics and prognostic implications for patients entering the MRC AML trials.
by: Peniket, A, et al.
Published: (1999)

AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results
by: Daver, N, et al.
Published: (2022)

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
by: Freeman, SD, et al.
Published: (2023)

Differential Analysis of Genetic, Epigenetic, and Cytogenetic Abnormalities in AML
by: Islam, M., et al.
Published: (2017)

Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
by: Bhatnagar, N, et al.
Published: (2016)

Molecular characterization of the chromosome 9q deletion in AML.
by: Side, L, et al.
Published: (2000)

Biodistribution and nuclear import of 111In-labeled HIV-1 tat peptide immunoconjugates after intravenous or intratumoural injection in tumour-bearing mice
by: Cornelissen, B, et al.
Published: (2006)

Outcomes of relapsed/refractory patients with IDH1/2 mutated AML treated with non-targeted therapy: results from the NCRI AML trials
by: Hills, R, et al.
Published: (2018)

Transformation of myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML)
by: Goh, Chermaine Yu Zhen
Published: (2021)

Gene expression profiling in MDS and AML: potential and future avenues.
by: Theilgaard-Mönch, K, et al.
Published: (2011)

High bax expression modulates response to treatment and survival in AML.
by: Truran, L, et al.
Published: (1999)

Shall we dance: evolving partnerships of targeted therapies for AML
by: Perl, AE, et al.
Published: (2022)

Azacitidine prolongs overall survival in older patients with Acute Myeloid Leukemia (AML) with poor prognostic karyotypes
by: Doehner, H, et al.
Published: (2017)

The first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results
by: Sallman, D, et al.
Published: (2021)

IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML.
by: Chan, L, et al.
Published: (2005)

Suppression Of Aml1/ETO Via siRNA Mediated Gene Knockdown And Its Effects On FOXO3 AND c-Myc Expression In Aml t (8,21) Cells
by: Ong, Si Min
Published: (2017)

Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML
by: Puram, Rishi V., et al.
Published: (2018)

Telomere length is an independent prognostic marker in MDS but not in de novo AML
by: Williams, J, et al.
Published: (2017)

Clonal dynamics of TEL-AML1+ childhood ALL: an in vivo model
by: Turati, V
Published: (2015)

Del (9q) AML: clinical and cytological characteristics and prognostic implications.
by: Peniket, A, et al.
Published: (2005)

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
by: Grimwade, D, et al.
Published: (1998)

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
by: Grimwade, D, et al.
Published: (2001)

Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia.
by: Hong, D, et al.
Published: (2008)

Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome.
by: Robinson, H, et al.
Published: (2003)

Physical and transcriptional characterization of the commonly deleted region in del(9q) AML.
by: Daly, S, et al.
Published: (2001)

Molecular MRD status and outcome after transplantation in NPM1-mutated AML
by: Dillon, R, et al.
Published: (2020)

ETV6/AML1 fusion by FISH in adult acute lymphoblastic leukemia
by: Al-Obaidi, M, et al.
Published: (2002)

Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection.
by: Cornelissen, B, et al.
Published: (2008)

Auger electron therapy using In-111-labelled F3 peptide
by: Cornelissen, B, et al.
Published: (2011)

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results
by: Daver, NG, et al.
Published: (2022)

Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase ib results
by: Daver, NG, et al.
Published: (2023)